Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
150%(3 trials)
Terminated
2(40%)

Phase Distribution

Ph phase_2
2
40%
Ph phase_1
2
40%
Ph phase_3
1
20%

Phase Distribution

2

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(2)
Terminated(2)

Detailed Status

Terminated2
Completed2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (40.0%)
Phase 22 (40.0%)
Phase 31 (20.0%)

Trials by Status

terminated240%
not_yet_recruiting120%
completed240%

Recent Activity

0 active trials
Showing 5 of 5
not_yet_recruitingphase_1

A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus

NCT06535412
completedphase_2

Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia

NCT04333420
terminatedphase_2

A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care

NCT05195749
terminatedphase_3

CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients

NCT04734873
completedphase_1

4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients

NCT00905632

Clinical Trials (5)

Showing 5 of 5 trials
NCT06535412Phase 1

A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus

Not Yet Recruiting
NCT04333420Phase 2

Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia

Completed
NCT05195749Phase 2

A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care

Terminated
NCT04734873Phase 3

CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients

Terminated
NCT00905632Phase 1

4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5